|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 83.33 EUR | +1.08% |
|
+1.36% | -11.11% |
| Jul. 08 | SANOFI : UBS maintains a Buy rating | ZD |
| Jul. 03 | SANOFI : Goldman Sachs reiterates its Neutral rating | ZD |
Sales 2024 by Business Segment
Sales 2024 by Geography
Historical Breakdown of Revenue by Business Segments
Operating Income: Breakdown by Business Segment
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Pharmaceutical Products | ||||||||||
Biopharma | - | - | - | 41.21B | 43.95B | |||||
CAPEX | - | - | - | -2.91B | -3.2B | |||||
Operating Income | - | - | - | 11.25B | 11.28B | |||||
Consumer Healthcare | 4.45B | 4.52B | 5.14B | 5.23B | - | |||||
CAPEX | -101M | -79M | -98M | -118M | - | |||||
Gross Profit | - | - | - | - | - | |||||
Operating Income | 1.42B | 1.49B | 1.81B | 1.44B | - | |||||
Pharmaceuticals Excl. Consumer Healthcare | 25.8B | 27.23B | 31.34B | - | - | |||||
CAPEX | -1.29B | -1.47B | -1.49B | - | - | |||||
Gross Profit | - | - | - | - | - | |||||
Operating Income | 8.83B | 9.41B | 11.04B | - | - | |||||
Vaccines | 7.11B | 7.42B | 8.9B | - | - | |||||
CAPEX | -726M | -490M | -615M | - | - | |||||
Gross Profit | - | - | - | - | - | |||||
Operating Income | 2.28B | 2.61B | 3.17B | - | - | |||||
Pharmaceuticals | - | - | - | - | - | |||||
CAPEX | - | - | - | - | - | |||||
Gross Profit | - | - | - | - | - | |||||
Operating Income | - | - | - | - | - | |||||
Veterinary Drugs | ||||||||||
Others | - | - | 7M | - | 339M | |||||
Operating Income | -2.77B | -2.8B | -2.98B | -15M | 58M | |||||
Operating Income | - | - | - | - | - | |||||
Operating Income | - | - | - | - | - |
Geographical Revenue Distribution History
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
United States | 13.46B | 14.38B | 18.28B | 18.51B | 19.99B | |||||
Total Assets | 1.9B | 2.23B | 2.46B | 2.32B | 21.12B | |||||
Rest of The World | 7.76B | 7.85B | 8.39B | 13.46B | 12.07B | |||||
Total Assets | 2.4B | 2.23B | 2.42B | 2.09B | 2.74B | |||||
Europe (Excluding France) | - | - | - | 8.01B | 7.21B | |||||
Total Assets | 8.98B | 9.76B | 8.75B | 8.14B | 5.74B | |||||
France | - | - | - | 2.38B | 1.81B | |||||
Total Assets | 3.19B | 3.25B | 2.88B | 3.08B | 3.11B | |||||
Europe (Excl. Russia) | 9.15B | 9.76B | 10B | - | - | |||||
China | 2.45B | 2.72B | 3.12B | - | - | |||||
Russia | 641M | 575M | 674M | - | - | |||||
Brazil | 836M | 815M | 927M | - | - | |||||
South Korea | - | - | - | - | - | |||||
Asia (Excl. South Asia) | - | - | - | - | - | |||||
Total Assets | 44.36B | 48.06B | 49.89B | 49.4B | 43.38B | |||||
Africa, Middle East and South Asia | - | - | - | - | - | |||||
Eurasia | - | - | - | - | - | |||||
Africa, Middle East | - | - | - | - | - | |||||
Western Europe | - | - | - | - | - | |||||
Asia | - | - | - | - | - | |||||
Other Emerging Markets | - | - | - | - | - | |||||
North America (Excluding United States) | - | - | - | 704M | - | |||||
Total Assets | 11.32B | 13.95B | 15B | 18.85B | - | |||||
Latin America | - | - | - | - | - | |||||
Japan | 1.74B | 1.66B | 1.61B | - | - | |||||
Eastern Europe, Russia and Turkey | - | - | - | - | - | |||||
Europe | - | - | - | - | - |
- Stock Market
- Equities
- SAN Stock
- Financials Sanofi
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
